Neil Parrott
Overview
Explore the profile of Neil Parrott including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
1478
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Van der Veken M, Aertsen M, Brouwers J, Stillhart C, Parrott N, Augustijns P
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765337
In the original publication [...].
12.
Andrews-Morger A, Reutlinger M, Parrott N, Olivares-Morales A
Mol Pharm
. 2023 Sep;
20(10):5052-5065.
PMID: 37713584
During drug discovery and development, achieving appropriate pharmacokinetics is key to establishment of the efficacy and safety of new drugs. Physiologically based pharmacokinetic (PBPK) models integrating -to- extrapolation have become...
13.
Duthaler U, Bachmann F, Ozbey A, Umehara K, Parrott N, Fowler S, et al.
Clin Pharmacokinet
. 2023 Jun;
62(8):1141-1155.
PMID: 37328712
Background And Objective: The impact of liver cirrhosis on the activity of UDP-glucuronosyltransferases (UGTs) is currently not well characterized. We investigated the glucuronidation capacity and glucuronide accumulation in patients with...
14.
Kesisoglou F, Basu S, Belubbi T, Bransford P, Chung J, Dodd S, et al.
AAPS J
. 2023 Jun;
25(4):60.
PMID: 37322223
Current regulatory guidelines on drug-food interactions recommend an early assessment of food effect to inform clinical dosing instructions, as well as a pivotal food effect study on the to-be-marketed formulation...
15.
Manevski N, Umehara K, Parrott N
Mol Pharm
. 2023 May;
20(7):3438-3459.
PMID: 37235687
Hepatocyte intrinsic clearance (CL) and methods of in vitro-in vivo extrapolation (IVIVE) are often used to predict plasma clearance (CL) in drug discovery. While the prediction success of this approach...
16.
Ozbey A, Bachmann F, Duthaler U, Annaert P, Fowler S, Umehara K, et al.
Clin Pharmacol Ther
. 2023 Apr;
113(6):1346-1358.
PMID: 37017611
Failure to perform adequate dose adjustment in patients with liver cirrhosis may be associated with increased toxicity. We compared the prediction of area under the curve (AUC) and clearance for...
17.
Meneses-Lorente G, Guerini E, Mercier F, Parrott N, Kowalski K, Chow-Maneval E, et al.
Cancer Chemother Pharmacol
. 2023 Mar;
91(3):239-246.
PMID: 36884068
Purpose: Entrectinib is a central nervous system-active potent inhibitor of tropomyosin receptor kinase (TRK), with anti-tumor activity against neurotrophic NTRK gene fusion-positive tumors. This study investigates the pharmacokinetics of entrectinib...
18.
Belubbi T, Bassani D, Stillhart C, Parrott N
Pharmaceutics
. 2023 Jan;
15(1).
PMID: 36678820
Basmisanil, is a lipophilic drug substance, exhibiting poor solubility and good permeability (BCS class 2). A validated physiologically based biopharmaceutics model (PBBM) has been previously described for tablets dosed in...
19.
Ekiciler A, Chen W, Bo Y, Pugliano A, Donzelli M, Parrott N, et al.
Drug Metab Dispos
. 2022 Dec;
51(3):276-284.
PMID: 36460477
Reliable in vitro to in vivo translation of cytochrome P450 (CYP) 3A4 induction potential is essential to support risk mitigation for compounds during pharmaceutical discovery and development. In this study,...
20.
Parrott N, Manevski N, Olivares-Morales A
Mol Pharm
. 2022 Sep;
19(11):3858-3868.
PMID: 36150125
While high lipophilicity tends to improve potency, its effects on pharmacokinetics (PK) are complex and often unfavorable. To predict clinical PK in early drug discovery, we built human physiologically based...